Patients without antiphospholipid syndrome should receive a DOAC. DOACs are preferred over vitamin K antagonists such as warfarin/coumadin.
From the 2019 ASH guideline:
2021 ACCP clinical guideline recommendations:
Oct
6
2021
Patients without antiphospholipid syndrome should receive a DOAC. DOACs are preferred over vitamin K antagonists such as warfarin/coumadin.
From the 2019 ASH guideline:
2021 ACCP clinical guideline recommendations: